David Kung-Chun Chiu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11643608/publications.pdf

Version: 2024-02-01

19 2,663 15 19 g-index

19 19 19 19 4491

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Poloâ€like kinase 4 inhibitor CFIâ€400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. Hepatology, 2023, 77, 729-744.	7.3	16
2	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‣1. Hepatology Communications, 2022, 6, 178-193.	4.3	16
3	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. Nature Communications, 2022, 13, 954.	12.8	38
4	Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. Cell Reports, 2021, 34, 108676.	6.4	30
5	Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species. Hepatology, 2021, 74, 776-796.	7.3	13
6	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology, 2020, 159, 609-623.	1.3	100
7	Assessment of Stabilization and Activity of the HIFs Important for Hypoxia-Induced Signalling in Cancer Cells. Methods in Molecular Biology, 2019, 1928, 77-99.	0.9	5
8	Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death and Disease, 2019, 10, 934.	6.3	98
9	Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology, 2019, 69, 1768-1786.	7.3	111
10	RNA N6â€methyladenosine methyltransferaseâ€like 3 promotes liver cancer progression through YTHDF2â€dependent posttranscriptional silencing of SOCS2. Hepatology, 2018, 67, 2254-2270.	7.3	980
11	Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis, 2018, 7, 44.	4.9	31
12	Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. Journal of Hepatology, 2017, 67, 758-769.	3.7	118
13	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nature Communications, 2017, 8, 517.	12.8	319
14	Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. Journal of Clinical Investigation, 2017, 127, 1856-1872.	8.2	100
15	Hypoxia induces myeloidâ€derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C motif) ligand 26. Hepatology, 2016, 64, 797-813.	7.3	170
16	NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma. Clinical Cancer Research, 2016, 22, 3105-3117.	7.0	68
17	Transketolase counteracts oxidative stress to drive cancer development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E725-34.	7.1	186
18	Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis. PLoS ONE, 2014, 9, e115036.	2.5	67

#	Article	IF	CITATIONS
19	Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology, 2014, 60, 1645-1658.	7.3	197